Regulation of biosimilars: considerations in the development of biosimilars in an evolving landscape
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Presentation
- By: ANDERSON, Scott (Pfizer Inc., Worldwide Safety and Regulatory, San diego, United States of America)
The promise afforded by the prospect of biosimilars is to enable patient access to affordable high quality products which are as safe and effective as the original products. Legislation and Guidance development pertaining to biosimilars is occurring at different rates throughout the world. Development expectations also vary; some countries have an .. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.